Tekla Life Sciences Investors (HQL) Earnings Analysis
Tekla Life Sciences Investors (HQL) has no confirmed upcoming earnings date. Trailing P/E 2.92.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does HQL next report earnings?
No confirmed upcoming earnings date is currently scheduled for HQL. This page updates as the calendar is published.
HQL earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2024-12-09 | 1.22 USD | n/a | n/a | n/a |
HQL valuation and analyst view
| Trailing P/E | 2.92 |
|---|---|
| Trailing EPS | 6.517 USD |
| Price / book | 1.07 |
| Dividend yield | 10.35% |
| Market cap | 0.60B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Tekla Life Sciences Investors (HQL)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for HQL. This page updates as the calendar is published.
Did HQL beat earnings last quarter?
Consensus estimate data was not available for HQL's 2024-12-09 report.
What is HQL's current P/E ratio and EPS?
HQL trades at a trailing P/E of 2.92 on trailing EPS of 6.516990240017395 USD.
What do analysts rate HQL?
HQL has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.